NPI: 1306992151 · SEATTLE, WA 98122 · General Acute Care Hospital · NPI assigned 01/26/2007
Authorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
| Authorized Official | ANDERSON, DONALD (ASSISTANT SECREATRY FOR ENROLLMENT) |
| NPI Enumeration Date | 01/26/2007 |
Other providers sharing the same authorized official: ANDERSON, DONALD
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 440,193 | $18.13M |
| 2019 | 466,151 | $19.50M |
| 2020 | 396,416 | $16.30M |
| 2021 | 497,645 | $20.36M |
| 2022 | 475,215 | $19.12M |
| 2023 | 454,675 | $17.38M |
| 2024 | 399,784 | $14.73M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 49,534 | 40,819 | $15.42M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 115,736 | 107,666 | $13.55M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 91,896 | 84,596 | $8.25M |
| J9271 | Injection, pembrolizumab, 1 mg | 2,006 | 1,488 | $7.90M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 114,067 | 77,667 | $7.45M |
| 77412 | 14,108 | 1,410 | $5.28M | |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 63,117 | 58,594 | $5.16M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 17,758 | 17,002 | $3.22M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 10,024 | 7,242 | $2.47M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 28,073 | 26,251 | $2.44M |
| J9263 | Injection, oxaliplatin, 0.5 mg | 2,941 | 913 | $2.41M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 23,157 | 18,104 | $2.17M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5,711 | 5,577 | $2.10M |
| J2350 | Injection, ocrelizumab, 1 mg | 210 | 188 | $2.03M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 22,745 | 13,708 | $1.90M |
| 70450 | Computed tomography, head or brain; without contrast material | 13,406 | 12,726 | $1.87M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 15,549 | 13,118 | $1.70M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,373 | 1,193 | $1.58M |
| J2323 | Injection, natalizumab, 1 mg | 705 | 658 | $1.48M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 4,512 | 4,423 | $1.40M |
| 96415 | 7,743 | 5,256 | $1.36M | |
| 59025 | Fetal non-stress test | 8,629 | 5,266 | $1.24M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 10,131 | 9,392 | $1.23M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2,454 | 2,409 | $1.14M |
| J2505 | Injection, pegfilgrastim, 6 mg | 705 | 468 | $1.09M |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 826 | 529 | $1.06M |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 999 | 574 | $1.03M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5,779 | 5,603 | $1.01M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 5,596 | 5,412 | $984K |
| J9035 | Injection, bevacizumab, 10 mg | 662 | 352 | $789K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 8,620 | 8,237 | $772K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 20,609 | 18,582 | $727K |
| 10060 | 3,374 | 3,263 | $704K | |
| 90870 | 2,185 | 664 | $557K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 8,551 | 5,128 | $556K |
| 96416 | 2,632 | 1,526 | $549K | |
| 12001 | 2,587 | 2,542 | $537K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 10,352 | 6,745 | $521K |
| 80053 | Comprehensive metabolic panel | 121,503 | 97,685 | $518K |
| J9306 | Injection, pertuzumab, 1 mg | 378 | 269 | $496K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1,169 | 1,156 | $472K |
| 76642 | 5,622 | 5,210 | $467K | |
| 76830 | Ultrasound, transvaginal | 5,656 | 5,475 | $466K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5,873 | 5,498 | $466K |
| Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | 317 | 205 | $463K |
| 76801 | 8,150 | 7,478 | $419K | |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,932 | 842 | $403K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 6,797 | 6,621 | $403K |
| 87631 | 5,470 | 5,279 | $394K | |
| 12011 | 1,663 | 1,636 | $377K | |
| 93970 | 3,639 | 3,519 | $362K | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | 204 | 193 | $353K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 6,462 | 6,277 | $349K |
| 70498 | 3,360 | 3,265 | $343K | |
| 96367 | 5,868 | 4,145 | $332K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 7,970 | 7,878 | $321K |
| 76770 | 2,490 | 2,441 | $319K | |
| J1453 | Injection, fosaprepitant, 1 mg | 3,852 | 2,390 | $301K |
| 70496 | 3,365 | 3,268 | $283K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1,329 | 1,300 | $279K |
| 10061 | 1,524 | 1,472 | $275K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1,952 | 1,899 | $274K |
| 12002 | 1,396 | 1,372 | $269K | |
| 77334 | 1,861 | 1,320 | $253K | |
| G0378 | Hospital observation service, per hour | 21,082 | 9,101 | $246K |
| 77336 | 4,839 | 2,036 | $243K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1,131 | 1,093 | $240K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 5,331 | 4,751 | $239K |
| 93971 | 2,522 | 2,461 | $228K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 3,863 | 3,751 | $217K |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | 135 | 92 | $210K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 7,143 | 6,137 | $193K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 7,911 | 3,094 | $191K |
| 70491 | 1,334 | 1,307 | $186K | |
| J9395 | Injection, fulvestrant, 25 mg | 635 | 565 | $185K |
| 80047 | 49,111 | 45,498 | $177K | |
| 84484 | 42,043 | 33,714 | $174K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | 1,052 | 730 | $172K |
| 76818 | 5,968 | 3,146 | $170K | |
| 36430 | 2,257 | 1,477 | $166K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7,605 | 3,559 | $165K |
| 19083 | 261 | 250 | $157K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 14,856 | 14,305 | $147K |
| J1756 | Injection, iron sucrose, 1 mg | 4,789 | 2,564 | $136K |
| J0185 | Injection, aprepitant, 1 mg | 1,719 | 1,081 | $132K |
| 64400 | 465 | 441 | $131K | |
| 43235 | 377 | 370 | $128K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 16,042 | 10,614 | $125K |
| 77290 | 586 | 544 | $122K | |
| 77065 | Tomosynthesis, mammo | 3,874 | 3,569 | $117K |
| 83605 | 22,678 | 19,296 | $117K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 26,850 | 21,697 | $115K |
| 93978 | 2,561 | 2,465 | $114K | |
| 76870 | 1,247 | 1,192 | $112K | |
| 29125 | 915 | 897 | $109K | |
| 77066 | Tomosynthesis, mammo | 3,797 | 3,728 | $109K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1,980 | 1,917 | $108K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 446 | 428 | $107K |
| 80076 | 31,153 | 29,204 | $106K | |
| 77295 | 255 | 234 | $102K | |
| 77386 | 379 | 37 | $101K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8,917 | 8,543 | $97K |
| 64483 | 220 | 212 | $88K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 6,874 | 6,454 | $88K |
| J9312 | Injection, rituximab, 10 mg | 31 | 26 | $87K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 2,768 | 1,213 | $87K |
| 71046 | Radiologic examination, chest; 2 views | 17,962 | 17,273 | $86K |
| 90715 | 4,525 | 4,426 | $85K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 693 | 671 | $82K |
| 93976 | 1,674 | 1,619 | $79K | |
| J9206 | Injection, irinotecan, 20 mg | 975 | 477 | $78K |
| 36561 | 85 | 80 | $78K | |
| 36415 | Collection of venous blood by venipuncture | 41,917 | 31,167 | $78K |
| 70486 | 2,364 | 2,313 | $78K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 64,772 | 56,668 | $74K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 5,373 | 5,318 | $71K |
| 87040 | 11,634 | 6,628 | $69K | |
| 76819 | Fetal biophysical profile; without non-stress testing | 1,703 | 1,352 | $69K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 181,739 | 146,276 | $67K |
| 77470 | 102 | 100 | $65K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 2,178 | 2,106 | $63K |
| 77280 | 376 | 333 | $58K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2,710 | 1,227 | $56K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3,890 | 3,628 | $54K |
| 87400 | 3,850 | 2,839 | $53K | |
| 84145 | 6,368 | 5,847 | $51K | |
| 74174 | 557 | 531 | $48K | |
| 86300 | 4,699 | 3,993 | $46K | |
| 97162 | 1,697 | 1,619 | $46K | |
| 96523 | 1,381 | 1,303 | $46K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 53,354 | 47,669 | $46K |
| 83880 | 10,044 | 9,436 | $45K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 30,254 | 22,125 | $45K |
| 76813 | 1,384 | 1,338 | $44K | |
| J0897 | Injection, denosumab, 1 mg | 350 | 312 | $44K |
| 36591 | 7,874 | 6,348 | $43K | |
| 77300 | 969 | 863 | $43K | |
| 76820 | 1,647 | 846 | $42K | |
| 85379 | 8,353 | 8,102 | $41K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 4,996 | 4,671 | $41K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 2,572 | 1,607 | $40K |
| 76536 | 449 | 443 | $37K | |
| J1750 | Injection, iron dextran, 50 mg | 812 | 428 | $37K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 5,355 | 5,228 | $37K |
| 73630 | 5,856 | 5,514 | $34K | |
| 73562 | 3,366 | 3,278 | $33K | |
| 54161 | 71 | 68 | $32K | |
| 97161 | 1,025 | 983 | $32K | |
| 44970 | 13 | 13 | $32K | |
| 71045 | Radiologic examination, chest; single view | 28,550 | 26,765 | $32K |
| 72125 | Computed tomography, cervical spine; without contrast material | 3,709 | 3,578 | $32K |
| 73610 | 6,116 | 5,752 | $31K | |
| 47562 | 12 | 12 | $28K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 285 | 282 | $27K |
| 82105 | 2,838 | 2,668 | $26K | |
| J3489 | Injection, zoledronic acid, 1 mg | 946 | 898 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | 11,784 | 10,503 | $24K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3,028 | 2,884 | $24K |
| 77331 | 425 | 365 | $23K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1,205 | 1,166 | $23K |
| 73030 | 4,695 | 4,278 | $23K | |
| 72100 | 3,443 | 3,353 | $22K | |
| 71250 | 615 | 598 | $22K | |
| 73700 | 358 | 337 | $22K | |
| 97535 | Self-care/home management training, each 15 minutes | 2,251 | 1,327 | $22K |
| J2997 | Injection, alteplase recombinant, 1 mg | 572 | 485 | $22K |
| 73130 | 4,608 | 4,309 | $21K | |
| 82784 | 4,221 | 2,819 | $21K | |
| 93975 | 268 | 261 | $21K | |
| 88307 | 1,625 | 1,473 | $20K | |
| 82728 | 7,383 | 6,924 | $20K | |
| 97116 | 2,401 | 1,399 | $19K | |
| 80197 | 2,668 | 1,294 | $19K | |
| 87158 | 1,659 | 1,416 | $18K | |
| 91200 | 205 | 198 | $18K | |
| 70487 | 87 | 87 | $17K | |
| 64493 | 33 | 26 | $17K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 573 | 408 | $17K |
| 97166 | 836 | 792 | $17K | |
| 19081 | 24 | 24 | $17K | |
| 76937 | 587 | 546 | $17K | |
| 97165 | 671 | 641 | $17K | |
| 85027 | 16,527 | 14,275 | $17K | |
| 43264 | 46 | 42 | $17K | |
| 83735 | 17,523 | 11,844 | $17K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 63,183 | 47,553 | $16K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 85 | 82 | $16K |
| 77001 | 191 | 179 | $16K | |
| 82378 | 6,124 | 4,764 | $16K | |
| 74018 | 2,820 | 2,623 | $16K | |
| 73502 | 2,643 | 2,522 | $15K | |
| 86304 | 2,393 | 1,925 | $15K | |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 97 | 30 | $15K |
| 77387 | 2,438 | 239 | $14K | |
| 96368 | 3,593 | 2,288 | $14K | |
| 74183 | 64 | 63 | $14K | |
| 90686 | 1,291 | 1,254 | $14K | |
| 86923 | 1,567 | 1,193 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1,996 | 1,920 | $13K |
| J0515 | Injection, benztropine mesylate, per 1 mg | 362 | 334 | $13K |
| J9070 | Cyclophosphamide, 100 mg | 170 | 105 | $13K |
| 73701 | 65 | 64 | $13K | |
| J0485 | Injection, belatacept, 1 mg | 277 | 112 | $12K |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 70 | 25 | $12K |
| 73110 | 3,609 | 3,390 | $12K | |
| 76882 | 162 | 145 | $12K | |
| 87517 | 755 | 737 | $12K | |
| 87522 | Neg quan hep c or qual rna | 776 | 747 | $11K |
| 86317 | 1,354 | 1,267 | $10K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 32 | 13 | $10K |
| 88185 | 442 | 397 | $10K | |
| 85610 | 23,112 | 17,806 | $10K | |
| 72040 | 926 | 904 | $9K | |
| 73564 | 2,938 | 2,745 | $9K | |
| 82607 | 2,849 | 2,741 | $9K | |
| 87486 | 1,210 | 1,171 | $9K | |
| 87581 | 1,210 | 1,171 | $9K | |
| 83883 | 1,724 | 819 | $8K | |
| 87641 | 1,564 | 1,428 | $8K | |
| 96402 | 2,912 | 2,662 | $8K | |
| 80061 | Lipid panel | 1,755 | 1,732 | $8K |
| 84703 | 36,709 | 34,554 | $8K | |
| 84702 | 9,914 | 9,009 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 55,189 | 45,733 | $8K |
| 72141 | 67 | 64 | $8K | |
| 73140 | 2,633 | 2,500 | $8K | |
| 82962 | 31,111 | 18,095 | $7K | |
| 80050 | General health panel | 1,581 | 1,450 | $7K |
| 72158 | 75 | 74 | $7K | |
| 87507 | 110 | 109 | $7K | |
| 87799 | 990 | 755 | $7K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1,150 | 1,115 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 11,256 | 10,312 | $7K |
| 84100 | 7,761 | 4,879 | $6K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 18 | 15 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8,859 | 8,506 | $6K |
| 83540 | 6,533 | 6,203 | $6K | |
| 81001 | 34,001 | 31,106 | $6K | |
| 12013 | 38 | 38 | $6K | |
| 96409 | 558 | 312 | $6K | |
| 73080 | 2,171 | 2,074 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 14,142 | 13,290 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3,605 | 3,494 | $6K |
| 73590 | 2,063 | 1,893 | $6K | |
| 83690 | 42,492 | 38,968 | $6K | |
| 96376 | 16,817 | 12,537 | $6K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1,138 | 1,086 | $6K |
| 82570 | 5,653 | 4,127 | $6K | |
| 86140 | 13,740 | 12,439 | $6K | |
| 81003 | 46,159 | 39,396 | $6K | |
| 86301 | 607 | 440 | $6K | |
| 94060 | 104 | 100 | $5K | |
| 97163 | 159 | 147 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 5,734 | 5,537 | $5K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 91 | 90 | $5K |
| 71101 | 1,799 | 1,758 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 33,104 | 31,427 | $5K |
| 80143 | 495 | 469 | $5K | |
| 82553 | 633 | 594 | $4K | |
| 82565 | 4,312 | 3,739 | $4K | |
| 36593 | 156 | 145 | $4K | |
| 84156 | 5,619 | 4,024 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3,328 | 3,231 | $4K |
| 86803 | 1,999 | 1,933 | $4K | |
| 0001A | 164 | 162 | $4K | |
| 62323 | 12 | 12 | $4K | |
| 99195 | 102 | 86 | $4K | |
| 83970 | 349 | 234 | $4K | |
| 84466 | 2,392 | 2,301 | $4K | |
| 72072 | 492 | 486 | $4K | |
| 84439 | 3,786 | 3,304 | $4K | |
| C1781 | Mesh (implantable) | 65 | 65 | $4K |
| 86850 | 5,484 | 4,642 | $4K | |
| 20610 | 26 | 25 | $4K | |
| C1769 | Guide wire | 3,176 | 2,815 | $4K |
| 94729 | 159 | 153 | $4K | |
| 72131 | 109 | 105 | $3K | |
| 10160 | 16 | 14 | $3K | |
| 20553 | 63 | 53 | $3K | |
| 74330 | 27 | 25 | $3K | |
| 76942 | 57 | 54 | $3K | |
| 83615 | 6,944 | 5,502 | $3K | |
| 86901 | 8,920 | 6,794 | $3K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 134 | 126 | $3K |
| 86900 | 7,430 | 5,332 | $3K | |
| 80305 | 10,561 | 10,066 | $3K | |
| 83521 | 604 | 470 | $3K | |
| 84165 | 2,116 | 1,922 | $3K | |
| 62369 | 116 | 115 | $3K | |
| 80179 | 2,436 | 2,297 | $3K | |
| 96417 | 6,647 | 4,256 | $2K | |
| 73090 | 1,234 | 1,143 | $2K | |
| 87340 | 2,939 | 2,810 | $2K | |
| 84153 | 717 | 665 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 8,895 | 8,395 | $2K |
| 82746 | 1,789 | 1,729 | $2K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 2,983 | 1,610 | $2K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 54 | 53 | $2K |
| 96401 | 274 | 120 | $2K | |
| 36000 | 1,514 | 1,452 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 34,903 | 30,772 | $2K |
| 85014 | 3,963 | 3,297 | $2K | |
| 83550 | 2,482 | 2,336 | $2K | |
| 94726 | 71 | 69 | $2K | |
| 87081 | 3,009 | 2,854 | $2K | |
| 82075 | 3,107 | 2,734 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 32,481 | 24,869 | $2K |
| 73660 | 469 | 453 | $2K | |
| 88184 | 481 | 417 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 22,072 | 15,496 | $2K |
| 97035 | 276 | 146 | $2K | |
| 87593 | 37 | 35 | $2K | |
| 87210 | 6,310 | 6,073 | $2K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 209 | 176 | $2K |
| 87640 | 465 | 442 | $1K | |
| 82803 | 7,958 | 6,939 | $1K | |
| 84550 | 3,671 | 2,758 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 922 | 880 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,770 | 1,681 | $1K |
| 86592 | 1,357 | 1,310 | $1K | |
| 82550 | 3,373 | 3,006 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 11,915 | 8,965 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | 20,749 | 17,037 | $1K |
| 87205 | 5,875 | 5,249 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5,680 | 5,571 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 15,410 | 12,638 | $1K |
| 99152 | 2,161 | 2,030 | $1K | |
| 87186 | 4,929 | 4,676 | $1K | |
| 86704 | 1,710 | 1,647 | $1K | |
| J2704 | Injection, propofol, 10 mg | 20,422 | 18,079 | $1K |
| J2060 | Injection, lorazepam, 2 mg | 10,331 | 8,244 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5,039 | 2,626 | $1K |
| 87070 | 4,812 | 4,352 | $1K | |
| J3490 | Unclassified drugs | 4,542 | 3,766 | $1K |
| 77332 | 26 | 25 | $1K | |
| 72050 | 129 | 127 | $1K | |
| 85730 | 5,397 | 4,883 | $1K | |
| 87653 | 340 | 327 | $1K | |
| 72170 | 299 | 271 | $997.17 | |
| 86780 | 505 | 491 | $970.64 | |
| 85651 | 5,198 | 4,784 | $933.48 | |
| 80069 | 277 | 227 | $915.19 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 27,191 | 22,370 | $882.72 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 16,775 | 15,092 | $879.74 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 14,144 | 11,849 | $879.48 |
| 86334 | 305 | 265 | $868.95 | |
| 74019 | 206 | 203 | $865.40 | |
| 87497 | 115 | 81 | $862.45 | |
| 85652 | 2,870 | 2,713 | $843.51 | |
| 94770 | 12 | 12 | $841.86 | |
| 84163 | 70 | 68 | $818.70 | |
| 77080 | 14 | 14 | $803.18 | |
| 73560 | 183 | 177 | $783.66 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 15,689 | 12,028 | $737.14 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 13,539 | 11,401 | $734.10 |
| 77417 | 727 | 367 | $733.95 | |
| 88342 | 2,624 | 2,491 | $728.99 | |
| 89051 | 695 | 553 | $705.81 | |
| 74220 | 28 | 26 | $700.94 | |
| 86480 | 86 | 83 | $695.03 | |
| 73552 | 165 | 151 | $686.71 | |
| 87902 | 27 | 26 | $670.73 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 537 | 465 | $653.19 |
| 80051 | 625 | 495 | $610.18 | |
| 83010 | 104 | 93 | $605.27 | |
| 86038 | 464 | 441 | $601.34 | |
| G0379 | Direct admission of patient for hospital observation care | 128 | 125 | $579.68 |
| 99153 | Mod sedat endo service >5yrs | 3,158 | 3,047 | $559.86 |
| 82248 | 1,226 | 1,136 | $555.00 | |
| J9171 | Injection, docetaxel, 1 mg | 17 | 12 | $529.92 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 85 | 54 | $517.97 |
| 82150 | 2,868 | 2,704 | $497.98 | |
| 86706 | 477 | 465 | $484.31 | |
| 0031A | 15 | 14 | $484.29 | |
| 88341 | 1,082 | 1,011 | $478.75 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 4,321 | 3,683 | $471.86 |
| 73100 | 15 | 13 | $449.00 | |
| A4648 | Tissue marker, implantable, any type, each | 1,271 | 1,081 | $415.23 |
| 90656 | 51 | 51 | $400.81 | |
| 87075 | 2,340 | 2,010 | $384.56 | |
| 87150 | 629 | 602 | $377.84 | |
| 73060 | 108 | 103 | $376.25 | |
| 82077 | 981 | 906 | $364.36 | |
| J9045 | Injection, carboplatin, 50 mg | 2,663 | 1,652 | $362.51 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 848 | 788 | $361.83 |
| J9267 | Injection, paclitaxel, 1 mg | 3,108 | 1,401 | $359.94 |
| 91322 | 30 | 28 | $351.65 | |
| 87077 | 1,838 | 1,782 | $340.85 | |
| 91320 | 36 | 36 | $339.20 | |
| 84403 | 68 | 68 | $337.31 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3,051 | 2,881 | $336.62 |
| 85018 | 913 | 694 | $326.95 | |
| 87430 | 1,679 | 1,655 | $320.30 | |
| 86762 | 192 | 185 | $310.78 | |
| 84132 | 1,760 | 1,459 | $309.17 | |
| G0008 | Administration of influenza virus vaccine | 332 | 322 | $298.47 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 4,754 | 2,803 | $285.54 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 16,935 | 14,090 | $268.04 |
| 88304 | 1,401 | 1,368 | $267.09 | |
| A9270 | Non-covered item or service | 27,429 | 6,400 | $266.26 |
| 82533 | 55 | 41 | $266.21 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 2,863 | 2,775 | $262.19 |
| 86308 | 841 | 823 | $262.06 | |
| 87188 | 1,148 | 1,111 | $258.24 | |
| 81025 | 3,374 | 3,169 | $249.09 | |
| 84520 | 783 | 618 | $248.95 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 4,235 | 3,573 | $244.33 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 1,300 | 1,197 | $241.77 |
| J7050 | Infusion, normal saline solution, 250 cc | 22,360 | 10,123 | $241.65 |
| 96411 | 3,939 | 2,411 | $236.25 | |
| 87147 | 1,198 | 1,073 | $234.19 | |
| 86708 | 303 | 287 | $234.05 | |
| 86336 | 84 | 82 | $233.25 | |
| 74175 | 13 | 13 | $227.29 | |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | 51 | 37 | $218.68 |
| 85045 | 400 | 358 | $215.11 | |
| 80074 | 67 | 63 | $211.82 | |
| 84450 | 768 | 626 | $207.00 | |
| 80202 | 32 | 26 | $206.62 | |
| 70360 | 40 | 39 | $204.02 | |
| 84155 | 757 | 701 | $201.70 | |
| 85046 | 660 | 594 | $200.44 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 559 | 539 | $196.65 |
| C9113 | Injection, pantoprazole sodium, per vial | 3,576 | 2,436 | $183.37 |
| J1815 | Injection, insulin, per 5 units | 5,381 | 2,660 | $180.32 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 3,263 | 3,189 | $175.74 |
| 83516 | 81 | 58 | $170.10 | |
| 82330 | 205 | 165 | $163.51 | |
| 74022 | 243 | 233 | $162.43 | |
| 85049 | 552 | 440 | $155.24 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 6,313 | 5,609 | $154.19 |
| 87073 | 13 | 12 | $150.20 | |
| 72220 | 13 | 12 | $147.51 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 1,384 | 1,292 | $143.55 |
| 87807 | 440 | 434 | $142.31 | |
| 84460 | 715 | 578 | $139.20 | |
| 86644 | 95 | 86 | $138.17 | |
| 80178 | 18 | 15 | $135.60 | |
| 87493 | 26 | 26 | $129.60 | |
| 99406 | 244 | 239 | $129.41 | |
| 82525 | 101 | 97 | $128.03 | |
| J1644 | Injection, heparin sodium, per 1000 units | 8,859 | 4,145 | $120.10 |
| J3370 | Injection, vancomycin hcl, 500 mg | 5,717 | 3,614 | $115.22 |
| 87116 | 15 | 13 | $114.85 | |
| 83021 | 12 | 12 | $113.57 | |
| 82140 | 212 | 191 | $113.08 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 1,983 | 1,716 | $112.16 |
| 90480 | 58 | 56 | $111.57 | |
| 82010 | 528 | 500 | $110.53 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 6,354 | 4,064 | $110.32 |
| 87481 | 261 | 205 | $109.76 | |
| 73070 | 26 | 25 | $99.00 | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | 262 | 192 | $96.18 |
| 36592 | 27 | 25 | $91.96 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 1,128 | 644 | $87.26 |
| J1940 | Injection, furosemide, up to 20 mg | 1,414 | 1,120 | $86.71 |
| 84481 | 53 | 50 | $80.74 | |
| 82670 | 12 | 12 | $78.13 | |
| J3480 | Injection, potassium chloride, per 2 meq | 3,491 | 2,053 | $76.02 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 227 | 218 | $75.08 |
| 88311 | 45 | 37 | $74.36 | |
| 85384 | 157 | 135 | $71.58 | |
| 86787 | 69 | 64 | $70.82 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 6,248 | 4,722 | $68.56 |
| 88313 | 91 | 85 | $67.95 | |
| C1729 | Catheter, drainage | 334 | 246 | $57.06 |
| 85660 | 39 | 36 | $54.24 | |
| 82310 | 56 | 29 | $53.42 | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | 232 | 145 | $51.23 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 8,124 | 3,020 | $50.95 |
| C1788 | Port, indwelling (implantable) | 84 | 80 | $48.66 |
| 97026 | 47 | 37 | $46.98 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 3,260 | 2,412 | $45.92 |
| 0353U | 686 | 670 | $42.70 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 413 | 391 | $40.45 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 591 | 527 | $35.04 |
| 83001 | 13 | 12 | $33.58 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 1,560 | 960 | $32.66 |
| 82247 | 14 | 14 | $26.95 | |
| 88312 | 54 | 51 | $26.38 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 711 | 426 | $25.44 |
| J1790 | Injection, droperidol, up to 5 mg | 2,127 | 1,902 | $25.39 |
| 82947 | 129 | 123 | $24.69 | |
| 86665 | 16 | 13 | $23.88 | |
| 87071 | 102 | 100 | $23.11 | |
| 94761 | 504 | 491 | $22.91 | |
| J3411 | Injection, thiamine hcl, 100 mg | 1,736 | 1,180 | $22.89 |
| 82950 | 36 | 36 | $21.57 | |
| 82043 | 13 | 13 | $20.09 | |
| 88112 | 93 | 86 | $18.96 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 749 | 593 | $18.05 |
| J1630 | Injection, haloperidol, up to 5 mg | 1,928 | 1,649 | $17.68 |
| 85007 | 62 | 55 | $16.75 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 34,253 | 25,999 | $15.34 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 3,741 | 3,317 | $14.84 |
| 86735 | 16 | 15 | $12.21 | |
| 86765 | 16 | 15 | $12.21 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 3,801 | 1,319 | $11.22 |
| J9190 | Injection, fluorouracil, 500 mg | 5,642 | 1,827 | $11.20 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 1,111 | 985 | $9.84 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 142 | 103 | $8.42 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 123 | 112 | $8.38 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 1,907 | 1,833 | $7.30 |
| 85670 | 12 | 12 | $5.61 | |
| J3360 | Injection, diazepam, up to 5 mg | 461 | 433 | $5.30 |
| 84295 | 62 | 53 | $3.81 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 423 | 308 | $3.50 |
| 86905 | 17 | 12 | $3.19 | |
| J1836 | Injection, metronidazole, 10 mg | 698 | 569 | $3.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 575 | 491 | $1.46 |
| J1956 | Injection, levofloxacin, 250 mg | 338 | 301 | $1.42 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 249 | 236 | $1.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 297 | 264 | $0.41 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 1,420 | 841 | $0.24 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 824 | 473 | $0.20 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 509 | 268 | $0.17 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 852 | 698 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 261 | 211 | $0.00 |
| 0240U | 15 | 15 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 448 | 423 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 892 | 729 | $0.00 |
| 97814 | 47 | 37 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 328 | 285 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 198 | 168 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 194 | 169 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 247 | 242 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 305 | 279 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 153 | 123 | $0.00 |
| 89060 | 12 | 12 | $0.00 | |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | 82 | 79 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 134 | 129 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 281 | 233 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 39 | 29 | $0.00 |
| 87206 | 15 | 13 | $0.00 | |
| C9463 | Injection, aprepitant, 1 mg | 22 | 14 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 42 | 29 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 13 | 13 | $0.00 |
| 87154 | 25 | 25 | $0.00 | |
| 85008 | 27 | 25 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 65 | 56 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 13 | 12 | $0.00 |
| 51798 | 15 | 14 | $0.00 | |
| 96377 | 17 | 12 | $0.00 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 15 | 12 | $0.00 |
| 91303 | 14 | 14 | $0.00 | |
| 91035 | 12 | 12 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 238 | 229 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 718 | 669 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 1,328 | 1,127 | $0.00 |
| 88360 | 41 | 39 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 506 | 455 | $0.00 |
| 51702 | 136 | 121 | $0.00 | |
| J2359 | Injection, olanzapine, 0.5 mg | 190 | 161 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 55 | 51 | $0.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 39 | 37 | $0.00 |
| 97813 | 47 | 37 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 12 | 12 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 13 | 12 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 783 | 707 | $0.00 |
| G2215 | Take-home supply of nasal naloxone; 2-pack of 4mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | 27 | 27 | $0.00 |
| 96549 | 229 | 153 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 30 | 30 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 202 | 179 | $0.00 |
| 88333 | 14 | 12 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 81 | 77 | $0.00 |
| C1776 | Joint device (implantable) | 155 | 148 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 71 | 61 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 187 | 174 | $0.00 |
| 88173 | 50 | 36 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 28 | 28 | $0.00 |
| 29515 | 26 | 24 | $0.00 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 21 | 14 | $0.00 |
| 90653 | 12 | 12 | $0.00 |